FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087280807> ?p ?o ?g. }

• W2087280807 endingPage "433" @default.
• W2087280807 startingPage "429" @default.
• W2087280807 abstract "BackgroundAminopeptidase P (APP) plays an important role in the catabolism of kinins in human plasma, mostly for des-Arg9-bradykinin. Impaired degradation of this active bradykinin metabolite was found to be associated with a decreased APP activity in hypertensive patients who experienced angioedema while being treated with angiotensin I–converting enzyme inhibitors. The pathophysiology of hereditary angioedema is presently attributed only to a quantitative/qualitative C1 inhibitor (CI-INH) defect with increased bradykinin release.ObjectivesIn the context of androgen prophylaxis, increased CI-INH function cannot fully explain protection from angioedema attacks alone because of the limited reversion of the CI-INH defects. Therefore we hypothesized that androgen prophylaxis could enhance plasma APP activity.MethodsPatients with hereditary angioedema were investigated for plasma metallopeptidase activities responsible for kinin catabolism (APP, angiotensin I-converting enzyme, and carboxypeptidase N) and for CI-INH function in treated and untreated patients.ResultsAPP activity was asymmetrically distributed in untreated patients (n = 147): the mean value was significantly lower than the value in a reference healthy and unmedicated population (n = 116; P ≤ .001). Prophylaxis with androgen induced a significant increase in APP activity (P ≤ .001), whereas it did not affect the other metallopeptidase activities. In both patient groups, APP activity showed a significant inverse relationship to disease severity (P ≤ .001).ConclusionIn addition to the effect on circulating CI-INH levels, the increase in APP levels brought on by androgens could contribute to a more effective control of the kinin accumulation considered to be responsible for the symptoms of angioedema. Aminopeptidase P (APP) plays an important role in the catabolism of kinins in human plasma, mostly for des-Arg9-bradykinin. Impaired degradation of this active bradykinin metabolite was found to be associated with a decreased APP activity in hypertensive patients who experienced angioedema while being treated with angiotensin I–converting enzyme inhibitors. The pathophysiology of hereditary angioedema is presently attributed only to a quantitative/qualitative C1 inhibitor (CI-INH) defect with increased bradykinin release. In the context of androgen prophylaxis, increased CI-INH function cannot fully explain protection from angioedema attacks alone because of the limited reversion of the CI-INH defects. Therefore we hypothesized that androgen prophylaxis could enhance plasma APP activity. Patients with hereditary angioedema were investigated for plasma metallopeptidase activities responsible for kinin catabolism (APP, angiotensin I-converting enzyme, and carboxypeptidase N) and for CI-INH function in treated and untreated patients. APP activity was asymmetrically distributed in untreated patients (n = 147): the mean value was significantly lower than the value in a reference healthy and unmedicated population (n = 116; P ≤ .001). Prophylaxis with androgen induced a significant increase in APP activity (P ≤ .001), whereas it did not affect the other metallopeptidase activities. In both patient groups, APP activity showed a significant inverse relationship to disease severity (P ≤ .001). In addition to the effect on circulating CI-INH levels, the increase in APP levels brought on by androgens could contribute to a more effective control of the kinin accumulation considered to be responsible for the symptoms of angioedema." @default.
• W2087280807 created "2016-06-24" @default.
• W2087280807 creator A5009422519 @default.
• W2087280807 creator A5010088807 @default.
• W2087280807 creator A5020442643 @default.
• W2087280807 creator A5022609217 @default.
• W2087280807 creator A5035337724 @default.
• W2087280807 creator A5039488698 @default.
• W2087280807 creator A5044762180 @default.
• W2087280807 creator A5045287052 @default.
• W2087280807 creator A5057592368 @default.
• W2087280807 creator A5061998322 @default.
• W2087280807 creator A5080423383 @default.
• W2087280807 creator A5081352308 @default.
• W2087280807 date "2008-02-01" @default.
• W2087280807 modified "2023-10-16" @default.
• W2087280807 title "Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P" @default.
• W2087280807 cites W1777223861 @default.
• W2087280807 cites W1967102304 @default.
• W2087280807 cites W1967632907 @default.
• W2087280807 cites W1971042333 @default.
• W2087280807 cites W1972615658 @default.
• W2087280807 cites W1985590078 @default.
• W2087280807 cites W1985888974 @default.
• W2087280807 cites W1986207725 @default.
• W2087280807 cites W1990096048 @default.
• W2087280807 cites W1996992656 @default.
• W2087280807 cites W2004395480 @default.
• W2087280807 cites W2004587229 @default.
• W2087280807 cites W2017547967 @default.
• W2087280807 cites W2046048837 @default.
• W2087280807 cites W2054962591 @default.
• W2087280807 cites W2059486139 @default.
• W2087280807 cites W2074707482 @default.
• W2087280807 cites W2075005598 @default.
• W2087280807 cites W2102953371 @default.
• W2087280807 cites W2114202051 @default.
• W2087280807 cites W2115565372 @default.
• W2087280807 cites W2141319262 @default.
• W2087280807 cites W2142111531 @default.
• W2087280807 cites W2167403453 @default.
• W2087280807 cites W2292537710 @default.
• W2087280807 cites W4252939281 @default.
• W2087280807 doi "https://doi.org/10.1016/j.jaci.2007.10.048" @default.
• W2087280807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4126900" @default.
• W2087280807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18158172" @default.
• W2087280807 hasPublicationYear "2008" @default.
• W2087280807 type Work @default.
• W2087280807 sameAs 2087280807 @default.
• W2087280807 citedByCount "102" @default.
• W2087280807 countsByYear W20872808072012 @default.
• W2087280807 countsByYear W20872808072013 @default.
• W2087280807 countsByYear W20872808072014 @default.
• W2087280807 countsByYear W20872808072015 @default.
• W2087280807 countsByYear W20872808072016 @default.
• W2087280807 countsByYear W20872808072017 @default.
• W2087280807 countsByYear W20872808072018 @default.
• W2087280807 countsByYear W20872808072019 @default.
• W2087280807 countsByYear W20872808072020 @default.
• W2087280807 countsByYear W20872808072021 @default.
• W2087280807 countsByYear W20872808072022 @default.
• W2087280807 countsByYear W20872808072023 @default.
• W2087280807 crossrefType "journal-article" @default.
• W2087280807 hasAuthorship W2087280807A5009422519 @default.
• W2087280807 hasAuthorship W2087280807A5010088807 @default.
• W2087280807 hasAuthorship W2087280807A5020442643 @default.
• W2087280807 hasAuthorship W2087280807A5022609217 @default.
• W2087280807 hasAuthorship W2087280807A5035337724 @default.
• W2087280807 hasAuthorship W2087280807A5039488698 @default.
• W2087280807 hasAuthorship W2087280807A5044762180 @default.
• W2087280807 hasAuthorship W2087280807A5045287052 @default.
• W2087280807 hasAuthorship W2087280807A5057592368 @default.
• W2087280807 hasAuthorship W2087280807A5061998322 @default.
• W2087280807 hasAuthorship W2087280807A5080423383 @default.
• W2087280807 hasAuthorship W2087280807A5081352308 @default.
• W2087280807 hasBestOaLocation W20872808074 @default.
• W2087280807 hasConcept C126322002 @default.
• W2087280807 hasConcept C134018914 @default.
• W2087280807 hasConcept C170493617 @default.
• W2087280807 hasConcept C185592680 @default.
• W2087280807 hasConcept C203014093 @default.
• W2087280807 hasConcept C27016395 @default.
• W2087280807 hasConcept C2776246183 @default.
• W2087280807 hasConcept C2776580952 @default.
• W2087280807 hasConcept C2777788586 @default.
• W2087280807 hasConcept C2777995640 @default.
• W2087280807 hasConcept C2779591629 @default.
• W2087280807 hasConcept C2780985610 @default.
• W2087280807 hasConcept C515207424 @default.
• W2087280807 hasConcept C55493867 @default.
• W2087280807 hasConcept C71924100 @default.
• W2087280807 hasConcept C84393581 @default.
• W2087280807 hasConceptScore W2087280807C126322002 @default.
• W2087280807 hasConceptScore W2087280807C134018914 @default.
• W2087280807 hasConceptScore W2087280807C170493617 @default.
• W2087280807 hasConceptScore W2087280807C185592680 @default.
• W2087280807 hasConceptScore W2087280807C203014093 @default.
• W2087280807 hasConceptScore W2087280807C27016395 @default.

• next